Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Piperno-Neumann

Showing results (61-70 of 148) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 15, 2018
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcomaThomas Brodowicz, Olivier Mir, Jennifer Wallet, et al.
Orthopaedics & Traumatology, Surgery & Research : OTSR|April 10, 2019
Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS)Anne Gomez-Brouchet, Eric Mascard, Aurore Siegfried, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyNicolas Penel, Binh Nguyen Bui, Jacques-Olivier Bay, et al.
Cancer|June 20, 2014
Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-upMaud Toulmonde, Axel Le Cesne, Jean Mendiboure, et al.
Cancer|July 22, 2014
Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks settingAntoine Italiano, Axel Le Cesne, Jean Mendiboure, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 7, 2022
L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastasesRaymond Barnhill, Steven van Laere, Peter Vermeulen, et al.
Pediatric Blood & Cancer|April 29, 2024
Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experiencePaul Bastard, Nathalie Cozic, Régis Brion, et al.
The Lancet. Oncology|November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 studyFlorence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
BMC Cancer|June 17, 2017
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective studyMarie-Dominique Tabone, Laurence Brugières, Sophie Piperno-Neumann, et al.
Annals of Surgery|February 27, 2023
Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal MelanomaPascale Mariani, François-Clément Bidard, Aurore Rampanou, et al.
Pageof 15

Showing results (61-70 of 148) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|June 15, 2018
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcomaThomas Brodowicz, Olivier Mir, Jennifer Wallet, et al.
Orthopaedics & Traumatology, Surgery & Research : OTSR|April 10, 2019
Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS)Anne Gomez-Brouchet, Eric Mascard, Aurore Siegfried, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyNicolas Penel, Binh Nguyen Bui, Jacques-Olivier Bay, et al.
Cancer|June 20, 2014
Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-upMaud Toulmonde, Axel Le Cesne, Jean Mendiboure, et al.
Cancer|July 22, 2014
Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks settingAntoine Italiano, Axel Le Cesne, Jean Mendiboure, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 7, 2022
L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastasesRaymond Barnhill, Steven van Laere, Peter Vermeulen, et al.
Pediatric Blood & Cancer|April 29, 2024
Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experiencePaul Bastard, Nathalie Cozic, Régis Brion, et al.
The Lancet. Oncology|November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 studyFlorence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
BMC Cancer|June 17, 2017
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective studyMarie-Dominique Tabone, Laurence Brugières, Sophie Piperno-Neumann, et al.
Annals of Surgery|February 27, 2023
Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal MelanomaPascale Mariani, François-Clément Bidard, Aurore Rampanou, et al.
Pageof 15